13F reference period
Q2 2026
Security Snapshot
Disc Medicine, Inc. - Common Stock, par value $0.0001 per share (IRON) Institutional Ownership
CUSIP: 254604101
13F Institutional Holders and Ownership History from Q4 2022 to Q3 2026
Institutions Reporting
215
Shares (Excl. Options)
42.77M
Full value: 42,768,316 · shares · 30 Jun 2026Price
$73.14
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- IRON on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 42,768,316
- Total 13F value
- $3,130,476,797
- Portfolio coverage rank
- 0%
- Share change
- +876,406
- Value change
- +$68,857,611
- Number of holders
- 215
- Shares outstanding
- 44,597,121
- SEC-reported price per share
- $60.48
- Insider filing price
- $60.48
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- IRON - Disc Medicine, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 254604101.
- 215 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 201 to 215 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$2.67B
Full value: $2,667,822,421 · USD · 31 Mar 2026.$3.13B
Full value: $3,130,476,797 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 215 institutions filings for Q2 2026.
Security key
254604101
13F reference period
Q2 2026
13F holders
215
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
IRON full holder history
Disc Medicine, Inc. SEC filings
Disc Medicine, Inc. company facts
Disc Medicine, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 254604101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
IRON
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 13% | -9.3% | $365,416,699 | -$2,374,866 | 4,875,473 | -0.65% | FMR LLC | 30 Jun 2026 |
| AI DMI LLC | 6.6% | -18% | $192,675,030 | -$4,912,758 | 2,943,410 | -2.5% | AI DMI LLC | 22 Oct 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 5.9% | $177,001,530 | 2,228,924 | RA Capital Management, L.P. | 30 Dec 2025 | |||
| ORBIMED ADVISORS LLC | 4.5% | $73,382,798 | 1,556,369 | ORBIMED ADVISORS LLC | 10 Mar 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 4.1% | -39% | $79,996,547 | -$50,911,307 | 1,432,090 | -39% | Wellington Management Group LLP | 30 Jun 2025 |
| Paradigm Biocapital Advisors LP | 3.5% | $57,097,283 | 1,210,971 | Paradigm BioCapital Advisors LP | 31 Mar 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 3% | $57,339,676 | 1,026,489 | Frazier Life Sciences Public Fund, L.P. | 30 Jun 2025 | |||
| Bain Capital Life Sciences Opportunities III, LP | 3.3% | $46,372,025 | 983,500 | Bain Capital Life Sciences Opportunities III, LP | 31 Dec 2024 | |||
| Atlas Venture Fund X, L.P. | 2.2% | -30% | $73,469,638 | -$24,517,376 | 813,167 | -25% | Atlas Venture Fund X, L.P. | 12 Dec 2025 |
As of 30 Jun 2026,
215
institutional investors reported holding
shares of
Disc Medicine, Inc. - Common Stock, par value $0.0001 per share (IRON).
This represents
96%
of the company’s total
outstanding shares.
42.77M
Full value: 42,768,316 · shares · 30 Jun 202644.6M
Full value: 44,597,121 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
75%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 11% | 4,894,473 | -12% | 0.02% | $357,981,753 |
| BlackRock, Inc. | 5.5% | 2,467,899 | +8.5% | 0% | $180,502,133 |
| RA CAPITAL MANAGEMENT, L.P. | 5.5% | 2,450,221 | 0% | 1.6% | $179,209,164 |
| JPMORGAN CHASE & CO | 4.2% | 1,875,795 | +37% | 0.01% | $139,868,053 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.2% | 1,875,399 | +21% | 0.01% | $137,168,000 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.9% | 1,741,351 | +0.34% | 0.02% | $127,362,413 |
| STATE STREET CORP | 3.7% | 1,648,836 | -2.9% | 0% | $120,595,865 |
| Vestal Point Capital, LP | 3.5% | 1,550,000 | +121% | 2.6% | $113,367,000 |
| Atlas Venture Life Science Advisors, LLC | 3.4% | 1,513,875 | 0% | 13% | $110,724,818 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 1,369,027 | -0.47% | 0% | $100,130,635 |
| Frazier Life Sciences Management, L.P. | 3% | 1,354,852 | 0% | 2.2% | $99,093,875 |
| TCG Crossover Management, LLC | 3% | 1,341,862 | 0% | 2.4% | $98,143,787 |
| BVF INC/IL | 2.6% | 1,153,612 | -9.3% | 2.2% | $84,375,182 |
| Woodline Partners LP | 2.1% | 958,281 | 0% | 0.22% | $70,088,672 |
| Siren, L.L.C. | 2% | 888,401 | -10% | 1.3% | $64,977,649 |
| Logos Global Management LP | 2% | 875,000 | +56% | 2.8% | $63,997,500 |
| Opaleye Management Inc. | 1.9% | 855,000 | +103% | 5.7% | $62,534,700 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 789,724 | +6.1% | 0% | $57,772,342 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.5% | 657,000 | 0% | 0.5% | $48,052,980 |
| DIMENSIONAL FUND ADVISORS LP | 1.3% | 569,018 | +44% | 0.01% | $41,622,451 |
| Bellevue Group AG | 1.3% | 560,000 | +22% | 0.86% | $40,958,400 |
| Saturn V Capital Management LP | 1.2% | 524,730 | +17% | 5.5% | $38,378,752 |
| ARMISTICE CAPITAL, LLC | 1% | 460,000 | -14% | 0.93% | $33,644,400 |
| JENNISON ASSOCIATES LLC | 0.99% | 439,520 | -28% | 0.02% | $32,146,492 |
| Aberdeen Group plc | 0.98% | 438,174 | +17% | 0.04% | $32,048,046 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
16
Headline period
Q2 2026
Rows shown
1-16 of 16
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,241,183 | $81,251,467 | +$46,646,555 | $65.46 | 28 |
| 2026 Q2 | 42,768,316 | $3,130,476,797 | +$68,857,611 | $73.14 | 215 |
| 2026 Q1 | 41,790,891 | $2,667,822,421 | +$184,842,529 | $63.94 | 201 |
| 2025 Q4 | 38,292,772 | $3,040,405,170 | +$327,723,771 | $79.41 | 196 |
| 2025 Q3 | 34,174,573 | $2,258,188,476 | +$16,098,753 | $66.08 | 164 |
| 2025 Q2 | 34,069,403 | $1,804,405,782 | +$52,373,227 | $52.96 | 148 |
| 2025 Q1 | 33,154,047 | $1,649,828,469 | +$313,979,403 | $49.64 | 155 |
| 2024 Q4 | 26,576,603 | $1,684,756,023 | -$53,215,124 | $63.40 | 151 |
| 2024 Q3 | 27,309,249 | $1,342,089,295 | -$26,632,908 | $49.14 | 130 |
| 2024 Q2 | 27,576,793 | $1,242,993,864 | +$212,594,407 | $45.07 | 119 |
| 2024 Q1 | 22,155,328 | $1,379,374,874 | +$124,372,681 | $62.26 | 125 |
| 2023 Q4 | 20,197,167 | $1,166,592,879 | +$18,737,189 | $57.76 | 111 |
| 2023 Q3 | 19,879,838 | $933,957,855 | +$42,877,645 | $46.98 | 90 |
| 2023 Q2 | 19,115,397 | $848,710,699 | +$223,083,623 | $44.40 | 89 |
| 2023 Q1 | 14,612,435 | $309,637,635 | +$77,103,451 | $21.19 | 45 |
| 2022 Q4 | 10,800,037 | $214,639,221 | +$202,496,221 | $19.89 | 30 |